Nebuhaler or nebulizer for high dose bronchodilator therapy in chronic bronchitis: a comparison

Allen, Martin; Pugh, Jenny; Wilson, Robert S.

doi:10.1016/0007-0971(88)90090-3

Cited by 10 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The included studies 260,270,[282][283][284][285][286][287][288][289][290][291][292] covered a broad range of individuals, location and types of comparison. Characteristics are detailed in Table 23.…”

Section: Review E: Bronchodilators For Stable and Acute Copd -Handhelmentioning

confidence: 99%

Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature

Brocklebank

Ram

Wright

et al. 2001

Health Technol Assess

352

197

View full text Add to dashboard Cite

et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001;5(26). Health Technology Assessment is indexed in Index Medicus/MEDLINE and Excerpta Medica/ EMBASE. Copies of the Executive Summaries are available from the NCCHTA website (see opposite). NHS R&D HTA Programme T he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme. This has meant that the HTA panels can now focus more explicitly on health technologies ('health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care) rather than settings of care. Therefore the panel structure has been redefined and replaced by three new panels: Pharmaceuticals; Therapeutic Procedures (including devices and operations); and Diagnostic Technologies and Screening. The HTA Programme will continue to commission both primary and secondary research. The HTA Commissioning Board, supported by the National Coordinating Centre for Health Technology Assessment (NCCHTA), will consider and advise the Programme Director on the best research projects to pursue in order to address the research priorities identified by the three HTA panels. The research reported in this monograph was funded as project number 97/23/02. The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors. Criteria for inclusion in the HTA monograph series Reports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors. Reviews in Health Technology Assessment are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

show abstract

Section: Review E: Bronchodilators For Stable and Acute Copd -Handhelmentioning

confidence: 99%

Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature

Brocklebank

Ram

Wright

et al. 2001

Health Technol Assess

352

197

View full text Add to dashboard Cite

show abstract

“…The development of newer bronchodilators at the end of 1970s slowly moved the interest of the journal towards this new therapeutic option. [141][142][143][144][145][146][147][148] Berend et al 141 documented that the bronchodilator response to salbutamol by intermittent positive pressure ventilation (IPPV), was greater than by metered dose inhaler (MDI) only in patients suffering from chronic obstructive bronchitis with severe airways obstruction and little additional benefit was gained with the 10 mg dose. Jenkins and Moxham 147 suggested that there is minimal if any benefit in terms of functional status administering regular doses above the equivalent of 200 mg of salbutamol four times daily in COPD, although pulmonary function (FEV 1 and PEFR, but not FVC) results showed a trend towards higher doses producing improved response and a longer duration of action, with bronchodilation following 2 mg significantly greater than 400 mg salbutamol.…”

Section: Bronchodilatorsmentioning

confidence: 99%

One hundred years of chronic obstructive pulmonary disease (COPD)

Cazzola

Donner

Hanania

2007

Respiratory Medicine

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is an increasing health problem and one of the leading causes of morbidity and mortality worldwide, but knowledge about its pathogenesis has increased substantially in recent years. The disease results from interaction between individual risk factors (like enzymatic deficiencies) and environmental exposures to noxious agents, like cigarette smoking, occupational dusts, air pollution and infections in childhood. The main mechanisms that may contribute to airflow limitation in COPD are fixed narrowing of small airways, emphysema and luminal obstruction with mucus secretions. COPD is characterised by a chronic inflammatory process in the pulmonary tissue, with a pattern different from bronchial asthma, associated with extrapulmonary effects and is considered now a complex, systemic disease. Optimal therapeutic targeting of COPD depends on a clear understanding of the precise mechanisms of these complex processes and on early and correct evaluation of disease severity. A combination of pharmacological and non-pharmacological approaches is used to treat COPD. Bronchodilators are the mainstay of COPD treatment and can be combined with inhaled corticosteroids for greater efficacy and fewer side effects. The use of LTOT for hypoxemic patients has resulted in increased survival, and expanded drug therapy options have effectively improved dyspnoea and quality of life. Recent studies have documented the benefits of pulmonary rehabilitation. In addition, non-invasive mechanical ventilation offers new alternatives for patients with acute or chronic failure.

show abstract